Global Regulators Explore Alignment Options During COVID-19
Executive Summary
Supporting convergence, allowing greater regulatory flexibility and avoiding drug shortages were among key topics discussed by global regulators at the first of a series of bi-weekly exchanges organized by the International Coalition of Medicines Regulatory Authorities.
You may also be interested in...
EU Launches Fast-Track Monitoring Of Crucial COVID-19 Drug Shortages
A new system for monitoring the availability of medicines for treating COVID-19 patients will allow EU-level coordinated actions to address supply shortages in the best way.
Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.